Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Navidea Biopharmaceuticals Inc (NAVB)

Navidea Biopharmaceuticals Inc (NAVB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,683
  • Shares Outstanding, K 30,367
  • Annual Sales, $ 530 K
  • Annual Income, $ -11,730 K
  • 60-Month Beta 1.38
  • Price/Sales 14.56
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NAVB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.40
  • Most Recent Earnings -0.10 on 08/15/22
  • Next Earnings Date 11/09/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 385.15% ( +385.15%)
  • Historical Volatility 75.01%
  • IV Percentile 94%
  • IV Rank 45.50%
  • IV High 799.51% on 07/15/22
  • IV Low 39.23% on 01/12/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 53
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 1.40
  • Today's Open Interest 4,616
  • Open Int (30-Day) 5,639

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2250 +12.44%
on 09/23/22
0.3700 -31.62%
on 08/31/22
-0.1170 (-31.62%)
since 08/30/22
3-Month
0.2250 +12.44%
on 09/23/22
0.7870 -67.85%
on 07/01/22
-0.4670 (-64.86%)
since 06/30/22
52-Week
0.2250 +12.44%
on 09/23/22
1.8300 -86.17%
on 10/04/21
-1.4970 (-85.54%)
since 09/30/21

Most Recent Stories

More News
Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Oral Ruling in Case Involving Attorney’s Fees

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Closing of its Rights Offering and Second Quarter 2022 Earnings Conference Call and Business Update

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Subscriptions of Approximately $14.2 Million from its Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Extension of Subscription Period to August 24, 2022 and Updated Terms of its Previously Announced Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced...

NAVB : 0.2530 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and...

See More

Key Turning Points

3rd Resistance Point 0.3297
2nd Resistance Point 0.3059
1st Resistance Point 0.2795
Last Price 0.2530
1st Support Level 0.2293
2nd Support Level 0.2055
3rd Support Level 0.1791

See More

52-Week High 1.8300
Fibonacci 61.8% 1.2169
Fibonacci 50% 1.0275
Fibonacci 38.2% 0.8381
Last Price 0.2530
52-Week Low 0.2250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar